VitaDAO

What is VitaDAO?

VitaDAO is a community-owned collective funding and supporting longevity science aimed at improving people's lives. VITA holders have the authority to choose the research they support, contribute to governance decisions, and advance the fight against age-related diseases.

In the pursuit of understanding aging, VitaDAO challenges conventional notions, delving into the world of longevity research to unearth its transformative potential in healthcare and quality of life enhancement for an aging population.

---

Recent Video Interview

Main points of the interview:

• VitaDAO funds early-stage longevity research, supporting projects from universities and private industry through its DAO model and VITA tokens.
• The DAO helps de-risk research, providing initial funding and incubation, and reinvests returns into new projects.
• VitaDAO uses IP NFTs and intellectual property tokens to secure and trade research assets.
• The community-driven model enables peer-reviewed evaluation of projects, improves research quality, and provides governance through Vita tokens.

---

Innovating with Special Economic Zones

VitaDAO delves into unconventional strategies to propel advancements in longevity science. Special Economic Zones are scrutinized as potent catalysts for accelerating breakthroughs in the field. VitaDAO's pioneering initiative, Zuzalu, serves as a testament to this exploration. This experimental pop-up city serves as a nexus where luminaries from the realms of longevity, cryptocurrency, and artificial intelligence converge.

By fostering interdisciplinary collaboration within Zuzalu's innovative framework, VitaDAO aims to harness collective expertise and resources to address the complex challenges of aging. Through this initiative, VitaDAO seeks to push the boundaries of traditional research methodologies, facilitating the rapid translation of scientific discoveries into tangible solutions for improving human health and longevity.

Empowering Longevity Innovation

VitaDAO stands as a globally distributed, community-owned entity dedicated to catalyzing progress in aging research. By funding and incubating translational projects, VitaDAO provides crucial support to initiatives often overlooked by conventional funding sources. Operating independently, VitaDAO has the flexibility to champion high-risk, high-reward endeavors that have the potential to redefine the landscape of aging science. Through its unique approach, VitaDAO fosters a collaborative environment where researchers, entrepreneurs, and enthusiasts unite to drive groundbreaking advancements.

By nurturing a diverse ecosystem of ideas and expertise, VitaDAO cultivates an environment conducive to innovation, where interdisciplinary collaboration thrives. With a shared commitment to pushing the boundaries of scientific discovery, VitaDAO empowers researchers to translate cutting-edge insights into tangible solutions that enhance human health and longevity on a global scale.

Longevity Science Projects Funded by VitaDAO

VitaDAO primarily funds translational R&D, particularly interested in ‘moonshots’ – potential revolutionary contributions to science. On occasion, they also fund more ‘basic’ research and other projects in the interests of the LongBio community.

Featured Projects:

• Discovering Novel Autophagy Activators - Korolchuk Lab
• Matrix Bio - Long-lived Species Inspired Longevity Biotech
• The Longevity Molecule - Scheibye-Knudsen Lab
• ApoptoSENS - Senolytic CAR-NK Cells
• Novel Mitophagy Activators for Alzheimer’s Disease - Fang Lab
• Reversing Periodontal Disease using Geroscience - An Lab
• Empowering Longevity Innovation

Team Background

The top scientific contributors to VitaDAO encompass a diverse range of expertise and experience. Diane Seimetz, an entrepreneur and regulatory expert, brings valuable insights into drug development. Neurogeneticist Jean M. Herbert from the Albert Einstein College of Medicine specializes in neurobiology, adding depth to the community's research endeavors. Marco Quarta, Co-Founder & CEO of Rubedo Life Sciences, provides leadership in biotech innovation.

Michael Baran, Executive Director at WRDM and Partner at Pfizer Ventures, brings a wealth of experience in venture investments and pharmaceuticals. Morten Scheibye-Knudsen, a leading longevity scientist, lends his expertise in aging research. Vera Gorbunova, Professor of Biology at the University of Rochester, contributes her knowledge in cellular aging and rejuvenation. Viktor Korolchuk, Reader in Molecular Cell Biology at Newcastle University, offers insights into cellular mechanisms.

Vittorio Sebastiano, Associate Professor at Stanford specializing in stem cell biology, adds expertise in regenerative medicine. Together, these contributors form a formidable team driving innovation and progress in longevity science within the VitaDAO community.

Partners

VitaDAO partners with Pfizer Ventures, Bankless DAO, PrimeDAO, Aura, Mantis Photonics, L1 Digital, Beaker DAO, Shine Capital, and more.

Project Development

VitaDAO, a global online community spearheading early-stage longevity research through innovative funding collaborations, has announced the launch of its inaugural biotech venture, Matrix Biosciences. This milestone follows a community-wide vote endorsing a partnership with Dr. Vera Gorbunova, Co-Chair of the University of Rochester’s Aging Research Center. Dr. Gorbunova expressed enthusiasm for the collaboration, emphasizing the potential of VitaDAO's support to propel Matrix Biosciences towards groundbreaking treatments for aging-related disorders and cancer.

The decision to establish Matrix Biosciences signifies a significant stride for VitaDAO as it advances its portfolio assets. Initial funding of $300,000 will kickstart preclinical studies aimed at testing novel hyaluronic acid-based compounds. Leveraging expertise from VitaDAO’s online community and Dr. Gorbunova’s team, Matrix Biosciences aims to identify promising drug candidates for therapeutic intervention.

Dr. Anthony Schwartz from VitaDAO praised the collaboration, highlighting the collective expertise driving the development strategy. He expressed optimism regarding early data and its potential for clinical translation. VitaDAO remains committed to efficient resource allocation in aging and longevity research, harnessing the academic community's talent to drive transformative advancements in aging-related diseases.

Matrix Biosciences focuses on developing high molecular weight hyaluronic acid (HMW-HA) therapeutics for cancer and aging-related diseases. Inspired by naked mole rats' longevity and cancer resistance attributed to HMW-HA abundance, the company aims to modulate hyaluronidases for potential applications in enhancing human healthspan and lifespan.

VitaDAO Price Analysis

As of December 21 2024 VitaDAO has a marketcap of $138M. This is {{percentagefromath}} from its all time high of $6.56. In terms of its tokenomics, there's a total supply of 27M with 95% currently outstanding. Keep in mind VitaDAO has a fully diluted value of $146M which many investors might interpret as overvalued.

Of course, don’t trust price predictions alone, always check the Coinrotator token screener to follow the trending market.